Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
100 μg KIO-301 · 1 trial · 1 indication
Change in ophthalmic and non-ophthalmic adverse events
| Arm | Type | Description |
|---|---|---|
| 50 μg KIO-301 | EXPERIMENTAL | 50 μg KIO-301 or placebo administered by IVT injection bilaterally (OU) once every 6 weeks for 3 administrations per participant. |
| 100 μg KIO-301 | EXPERIMENTAL | 100 μg KIO-301 or placebo administered by IVT injection OU once every 6 weeks for 3 administrations per participant. |
| Name | Type | Description |
|---|---|---|
| Placebo (Sterile Saline or Balanced Salt Solution) | OTHER | A control 50 μl injection of clear sterile saline or balanced salt solution (BSS) liquid. |
| 100 μg KIO-301 | DRUG | KIO-301 drug product is an ophthalmic formulation of the drug substance KIO-300-Cl in sulfobutylether-β-cyclodextrin, sucrose, phosphate buffer salts and water suitable for IVT injection. The drug substance KIO-300-Cl is a quaternary ammonium chloride salt of the active compound KIO-300. |
| 50 μg KIO-301 | DRUG | KIO-301 drug product is an ophthalmic formulation of the drug substance KIO-300-Cl in sulfobutylether-β-cyclodextrin, sucrose, phosphate buffer salts and water suitable for IVT injection. The drug substance KIO-300-Cl is a quaternary ammonium chloride salt of the active compound KIO-300. |
Inclusion Criteria: 1. Be aged 18 years or older at the time of consent. 2. Provide informed consent prior to any study procedures, as stipulated by local laws, Ethics Committee (EC) and Regulatory Authority (RA) guidelines. 3. Be willing and able to follow all study instructions, attend all study ...
KIO-301 is an investigational small molecule being developed for the treatment of retinitis pigmentosa, a group of inherited eye disorders that cause progressive vision loss. It is administered via intravitreal injection and is currently being studied in patients with late-stage disease.
KIO-301 is a small molecule designed to restore light sensitivity in the retina of patients with retinitis pigmentosa. It acts as a photoswitch, conferring light responsiveness to remaining retinal neurons that have lost their natural photoreceptors, thereby potentially restoring some visual function.
KIO-301 is being developed by Kiora Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol KPRX. The company is advancing the drug through clinical trials for the treatment of retinitis pigmentosa.
KIO-301 is currently in Phase 2 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing Phase 2 study is actively recruiting participants to evaluate its safety and efficacy in patients with late-stage retinitis pigmentosa.
KIO-301 is being evaluated in a Phase 2 clinical trial registered as NCT06628947. This randomized, double-blind, controlled study is recruiting 36 participants with late-stage retinitis pigmentosa at sites in Australia. The trial is currently in the recruiting stage and is not yet completed.
Yes, 100 μg KIO-301 refers to a specific dose of the drug KIO-301. The Phase 2 clinical trial NCT06628947 is investigating this particular dose administered via intravitreal injection in patients with late-stage retinitis pigmentosa.